| Bioactivity | TC299423 is an orally active, brain-penetrant, selective and potent agonist for α6β2∗ and α4β2∗ nicotinic acetylcholine receptors (nAChRs) with anxiolytic and antinociceptive properties. TC299423 acts primarily through α6β2∗ nAChRs that are implicated in the anxiolytic effects of nicotine. TC299423 elicits reward-related behavior mediated through α6β2∗ nAChRs in hypersensitive α6L90’S mice. TC299423 elicits dopamine release and dose not suppress nicotine self-administration in rats. TC299423 is proming for rasearch of addiction and Parkinson’s disease[1][2]. |
| CAS | 1975146-56-5 |
| Formula | C11H15N3 |
| Molar Mass | 189.26 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Wall TR, et al. TC299423, a Novel Agonist for Nicotinic Acetylcholine Receptors. Front Pharmacol. 2017 Sep 26;8:641. [2]. Post M R. Agonist Binding Studies at Two Subtypes of the Nicotinic Acetylcholine Receptor Involved in Parkinson’s Disease and Addiction[D]. California Institute of Technology, 2016. |